Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Novan, Inc.

Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
From Novan, Inc.
Via GlobeNewswire
Tickers LGND NOVN
Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders
From Novan, Inc.
Via GlobeNewswire
Tickers NOVN
Novan Focuses Strategic Direction and Announces Restructuring
From Novan, Inc.
Via GlobeNewswire
Tickers NOVN
Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Novan, Inc.
Via GlobeNewswire
Tickers NOVN
Novan to Report First Quarter 2023 Financial Results on May 15, 2023
From Novan, Inc.
Via GlobeNewswire
Tickers NOVN
Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹
From Novan, Inc.
Via GlobeNewswire
Tickers NOVN
Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD
From Novan, Inc.
Via GlobeNewswire
Tickers NOVN
Novan Reports Full Year 2022 Financial Results and Provides Corporate Update
From Novan, Inc.
Via GlobeNewswire
Tickers NOVN
Novan to Report Full Year 2022 Financial Results on March 30, 2023
From Novan, Inc.
Via GlobeNewswire
Tickers NOVN
Novan Announces Closing of $6.0 Million Registered Direct Offering
From Novan, Inc.
Via GlobeNewswire
Tickers NOVN
Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference
From Novan, Inc.
Via GlobeNewswire
Tickers NOVN
Novan Announces $6.0 Million Registered Direct Offering
From Novan, Inc.
Via GlobeNewswire
Tickers NOVN
Novan Moves Forward with Unified Corporate Branding
From Novan, Inc.
Via GlobeNewswire
Tickers NOVN
FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024
From Novan, Inc.
Via GlobeNewswire
Tickers NOVN
Novan to Present at the Virtual Investor 2023 Companies to Watch Event
From Novan, Inc.
Via GlobeNewswire
Tickers NOVN
Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
From Novan, Inc.
Via GlobeNewswire
Tickers NOVN
EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RHOFADE® in Japan
From Novan, Inc.
Via GlobeNewswire
Tickers NOVN
EPI Health, a Novan Company, Executes a $15.0 Million Financing Agreement
From Novan, Inc.
Via GlobeNewswire
Tickers HTBK NOVN
Novan to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference
From Novan, Inc.
Via GlobeNewswire
Tickers NOVN
Novan Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Novan, Inc.
Via GlobeNewswire
Tickers NOVN
Novan to Report Third Quarter 2022 Financial Results on November 14, 2022
From Novan, Inc.
Via GlobeNewswire
Tickers NOVN
EPI Health, a Novan Company, and MC2 Therapeutics Present New Data In Multiple Posters Highlighting WYNZORA’s® Unique PAD Technology™ at the 42nd Annual Fall Clinical Dermatology Conference®
From Novan, Inc.
Via GlobeNewswire
Tickers NOVN
EPI Health, a Novan Company, and MC2 Therapeutics Announce Data from Survey Conducted by National Psoriasis Foundation Presented at 42nd Annual Fall Clinical Dermatology Conference®
From Novan, Inc.
Via GlobeNewswire
Tickers NOVN
Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference®
From Novan, Inc.
Via GlobeNewswire
Tickers NOVN
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.